Myoridge Co. Ltd. and Hitachi, Ltd. have co-developed a novel three-dimensional (3D) cell culture technology to help realize the potential of regenerative medicine. The collaborative research underlying the new technology was initiated in October 2018 and combines Myoridge’s proprietary culture platform, including specialized medium and methodology, with Hitachi’s automated cell manufacturing bioreactor system. The new technology enables unprecedented uniform and high-density culture by utilizing cell spheroids formed through precise oscillation of the culture container, where the oscillation conditions are tailored to cell type and culture medium volume. In large-scale culture, this system provided a yield increase of several fold as well as remarkably increased cell quality compared to conventional culture in the same medium volume. The new technology is expected to contribute to the development of scalable, cost-effective manufacturing of cellular therapeutics in the amounts and quality required for widespread clinical application.